138 related articles for article (PubMed ID: 25559065)
1. Study of pharmacokinetic interaction of paroxetine and roxithromycin on bencycloquidium bromide in healthy subjects.
Agbokponto JE; Luo Z; Liu R; Liu Z; Liang M; Ding L
Eur J Pharm Sci; 2015 Mar; 69():37-43. PubMed ID: 25559065
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
[TBL] [Abstract][Full Text] [Related]
3. Safety, Tolerability and Pharmacokinetics of Bencycloquidium Bromide, a Novel Inhaled Anticholinergic Bronchodilator, in Healthy Subjects: Results from Phase I Studies.
Luo Z; Hu C; Pan Y; Miao J; Wang Y; Ding L; Liang M
Eur J Pharm Sci; 2021 Feb; 157():105646. PubMed ID: 33220462
[TBL] [Abstract][Full Text] [Related]
4. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
[TBL] [Abstract][Full Text] [Related]
5. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.
Ruiz-Garcia A; Giri N; LaBadie RR; Ni G; Boutros T; Richie N; Kocinsky HS; Checchio TM; Bello CL
J Clin Pharmacol; 2014 May; 54(5):555-62. PubMed ID: 24293056
[TBL] [Abstract][Full Text] [Related]
6. Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet.
Kapil RP; Friedman K; Cipriano A; Michels G; Shet M; Mondal SA; Harris SC
Clin Ther; 2015 Oct; 37(10):2286-96. PubMed ID: 26350273
[TBL] [Abstract][Full Text] [Related]
7. Subchronic toxicity and toxicokinetics of long-term intranasal administration of bencycloquidium bromide: a 91-day study in dogs.
Li J; He H; Zhou Y; Yuan P; Chen X
Regul Toxicol Pharmacol; 2011 Mar; 59(2):343-52. PubMed ID: 21130130
[TBL] [Abstract][Full Text] [Related]
8. In vitro metabolism of bencycloquidium bromide and its inhibitory effects on human P450 isoenzymes: implication of CYP2D6, CYP2C19 and CYP3A4/5.
Agbokponto JE; Zhang L; Hu L; Feng H; Ding L
Eur J Drug Metab Pharmacokinet; 2016 Feb; 41(1):69-77. PubMed ID: 25425116
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Solans A; Izquierdo I; Donado E; Antonijoan R; Peña J; Nadal T; Carbó ML; Merlos M; Barbanoj M
Clin Ther; 2008 Sep; 30(9):1639-50. PubMed ID: 18840369
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous determination and pharmacokinetic study of roxithromycin and ambroxol hydrochloride in human plasma by LC-MS/MS.
Hang TJ; Zhang M; Song M; Shen JP; Zhang YD
Clin Chim Acta; 2007 Jul; 382(1-2):20-4. PubMed ID: 17462615
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence evaluation of two roxithromycin formulations in healthy human volunteers by high performance liquid cromatography coupled to tandem mass spectrometry.
Motta M; Ribeiro W; Ifa DR; Moares ME; Moraes MO; Corrado AP; De Nucci G
Acta Physiol Pharmacol Ther Latinoam; 1999; 49(4):233-41. PubMed ID: 10797866
[TBL] [Abstract][Full Text] [Related]
12. Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN-812 (Viloxazine Extended-Release) Pharmacokinetics in Healthy Adults.
Wang Z; Kosheleff AR; Adeojo LW; Odebo O; Adewole T; Qin P; Maletic V; Schwabe S; Nasser A
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1365-1374. PubMed ID: 33943033
[TBL] [Abstract][Full Text] [Related]
13. The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers.
Schneider F; Stamler D; Bradbury MJ; Loupe PS; Gordon MF; Rabinovich-Guilatt L
Eur J Clin Pharmacol; 2022 Jan; 78(1):11-18. PubMed ID: 34491372
[TBL] [Abstract][Full Text] [Related]
14. Solid phase extraction and liquid chromatography-electrospray ionization-mass spectrometry for the determination of bencycloquidium bromide in human plasma.
Zhou W; Ding L; Wang Y; Sun L; Huang Y; Hu L; Chen X
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Apr; 877(10):897-901. PubMed ID: 19251489
[TBL] [Abstract][Full Text] [Related]
15. Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes.
Jung EH; Lee YJ; Kim DH; Kang P; Lim CW; Cho CK; Jang CG; Lee SY; Bae JW
Arch Pharm Res; 2020 Dec; 43(12):1356-1363. PubMed ID: 33245517
[TBL] [Abstract][Full Text] [Related]
16. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetics and relative bioavailability study of roxithromycin tablet in Chinese healthy volunteers by LC-MS/MS].
Zheng L; Qin Y; Nan F; Wang Y; Xu N; Liang M
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Dec; 26(6):1315-9. PubMed ID: 20095494
[TBL] [Abstract][Full Text] [Related]
18. Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects.
Dawra VK; Sahasrabudhe V; Liang Y; Matschke K; Shi H; Hickman A; Saur D; Terra SG; Cutler DL
Clin Ther; 2018 Sep; 40(9):1538-1547. PubMed ID: 30170758
[TBL] [Abstract][Full Text] [Related]
19. Potential interactions between cilostazol and probucol: a two-part, single-dose, open-label study in healthy Korean male volunteers.
Kim KP; Kim BH; Lim KS; Kim TE; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Oct; 31(10):2098-106. PubMed ID: 19922880
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic properties of once-daily oral low-dose mesylate salt of paroxetine (LDMP 7.5 mg) following single and multiple doses in healthy postmenopausal women.
Cristina Castelli M; Bhaskar S; Lippman J
Clin Ther; 2013 Jun; 35(6):862-9. PubMed ID: 23795577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
